## **OPTIMA HEALTH PLAN**

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process may be delayed.</u>

<u>Drug Requested</u> (select applicable drug below):	
□ <b>Soliqua</b> <sup>®</sup> (insulin glargine and lixisenatide injection)	□ Xultophy <sup>®</sup> (insulin degludec and liraglutide injection)
<b>DRUG INFORMATION:</b> Authorization may be delayed if incomplete.	
Drug Name/Form/Strength:	
Dosing Schedule:	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
<b>CLINICAL CRITERIA:</b> Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.	
<ul> <li>Patient has tried and failed at least 30 days of therapy with at least one drug from BOTH of the following drug classes:</li> <li>Glucagon-Like Peptide 1 Receptor Agonist:</li> </ul>	
D. D. (1) ®	
☐ Bydureon BCise®	□ Rybelsus <sup>®</sup> □ Trulicity <sup>®</sup>
☐ Ozempic <sup>®</sup>	□ Victoza <sup>®</sup>
AND	
<ul> <li>Long-Acting Insulin:</li> </ul>	
□ Lantus <sup>®</sup>	☐ Toujeo <sup>®</sup>
Not all drugs may be covered under every Plan  If a drug is non-formulary on a Plan, documentation of medical necessity will be required.  **Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.**  *Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*	
Patient Name:	
Member Optima #:	Date of Birth:
Prescriber Name:	
Prescriber Signature:	
Office Contact Name:	
Phone Number:	
DEA OR NPI #:	

\*Approved by the Pharmacy and Therapeutics Committee: 7/20/2017 REVISED/UPDATED: 9/4/2017; 7/30/2018; 3/25/2019; 8/31/2020; 6/30/2021